银屑病患者强制非医疗换用阿达木单抗生物类似药后的结局
丹麦全国DERMBIO登记队列研究比较了银屑病患者从阿达木单抗原研药强制非医疗换用生物类似药后的1年药物留存率。生物类似药队列348例,原研药队列378例,1年留存率分别为92.0%和92.1%,风险比无显著差异。结论认为强制非医疗换用与药物留存无关。
要点
- 强制非医疗换用阿达木单抗生物类似药后1年药物留存率与原研药相当。
- 因疗效不足或不良事件停药的风险比均无显著差异。
- 真实世界数据支持银屑病患者非医疗换用阿达木单抗生物类似药。
核心结论
- 在丹麦银屑病患者中,从阿达木单抗原研药非医疗换用生物类似药与药物留存无关。
研究设计与样本
- 基于丹麦全国DERMBIO登记(2007年起所有银屑病生物制剂治疗患者)的队列研究。
- 主要结局为1年药物留存率,采用Cox比例风险回归比较。
主要发现
- 生物类似药队列1年药物留存率92.0%(95%CI 89.0%-94.9%),原研药队列92.1%(95%CI 89.4%-94.8%)。
临床怎么用
- 银屑病患者可在医疗监督下从阿达木单抗原研药换用生物类似药,无需担心药物留存下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The efficacy of adalimumab biosimilars is similar to that of brand-name adalimumab (Humira, hereinafter originator) in clinical trials. However, limited knowledge about real-world data exists for adalimumab biosimilars. OBJECTIVE: To assess the outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis. DESIGN, SETTING, AND PARTICIPANTS: This cohort study assesses the outcomes following a switch from adalimumab originator to an adalimumab biosimilar. Patients in the Biological Treatment in Danish Dermatology (DERMBIO) registry, a Danish nationwide registry of all patients treated with biologics (including biosimilars) for psoriasis since 2007, were assessed for eligibility. All patients who switched from adalimumab originator to an adalimumab biosimilar between November 1, 2018, and May 1, 2019, were included in the adalimumab biosimilar cohort. All patients with a visit between May 1, 2017, and November 1, 2017, treated with adalimumab originator were included in the adalimumab originator cohort. Data were analyzed from June 1, 2020, to October 10, 2021. EXPOSURE: Switch from adalimumab originator to an adalimumab biosimilar. MAIN OUTCOMES AND MEASURES: The primary outcome was 1-year drug retention in patients switching to adalimumab biosimilars compared with patients treated with adalimumab originator. Crude and adjusted retention rates for the adalimumab biosimilar cohort were compared with the adalimumab originator cohort with Cox proportional hazards regression using robust variance. RESULTS: A total of 348 patients were included in the adalimumab biosimilar cohort (mean [SD] age, 52.2 [13.6] years; 251 [72.1%] male) and 378 patients in the adalimumab originator cohort (mean [SD] age, 51.1 [14.1] years; 272 [72.0%] male). The 1-year drug retention rates were 92.0% (95% CI, 89.0%-94.9%) for the adalimumab biosimilar cohort and 92.1% (95% CI, 89.4%-94.8%) for the adalimumab originator cohort. Similar hazard ratios were observed between the 2 cohorts. The crude hazard ratios were 1.02 (95% CI, 0.61-1.70; P = .94) for all causes of drug discontinuation, 0.82 (95% CI, 0.39-1.73; P = .60) for insufficient effect, and 1.41 (95% CI, 0.52-3.77; P = .50) for adverse events for the adalimumab biosimilar cohort when compared with the adalimumab originator cohort. CONCLUSIONS AND RELEVANCE: In this cohort study from Denmark, a nonmedical switch from adalimumab originator to adalimumab biosimilars was not associated with drug retention.
引用
- Loft N, Egeberg A, Rasmussen MK, et al. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis. JAMA Dermatol. 2021. PMID: 33825804. doi:10.1001/jamadermatol.2021.0221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。